April 25, 2022Open Access
View Full PaperEfficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction
Key Points
Key points are not available for this paper at this time.
Abstract
AstraZeneca.
Key points are not available for this paper at this time.
AstraZeneca.
Butt et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: